Ganciclovir treatment in children: Evidence of subtherapeutic levels

International Journal of Antimicrobial Agents

Volumn 37, Issue 5, 2011, Pages 445-448

  Luck, Suzanne ^a   Lovering, Andrew ^b   Griffiths, Paul ^a   Sharland, Mike ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Children; Cytomegalovirus; Ganciclovir; Therapeutic drug monitoring

Indexed keywords

GANCICLOVIR;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; GROUPS BY AGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT FAILURE; UNITED KINGDOM;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; GREAT BRITAIN; HUMANS; INFANT; INFANT, NEWBORN; PLASMA; YOUNG ADULT;

EID: 79953904643     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.11.033     Document Type: Article

References (17)

1. Jacqz-Aigrain E, Macher MA, Sauvageon-Marthe H, Brun P, Loirat C. Pharmacokinetics of ganciclovir in renal transplant children. Pediatr Nephrol 1992;6:194-6.
2. Zhang D, Lapeyraque AL, Popon M, Loirat C, Jacqz-Aigrain E. Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. Pediatr Nephrol 2003;18:943-8. (Pubitemid 37121631)
3. Trang JM, Kidd L, Gruber W, Storch G, Demmler G, Jacobs R, et al. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. Clin Pharmacol Ther 1993;53:15-21. (Pubitemid 23036683)
4. Zhou XJ, Gruber W, Demmler G, Jacobs R, Reuman P, Adler S, et al. Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. Antimicrob Agents Chemother 1996;40:2202-5. (Pubitemid 26296274)
5. Piketty C, Bardin C, Gilquin J, Gairard A, Kazatchkine MD, Chast F. Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis. Clin Microbiol Infect 2000;6:117-20. (Pubitemid 34960200)
6. Fishman JA, Doran MT, Volpicelli SA, Cosimi AB, Flood JG, Rubin RH. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2000;69:389-94. (Pubitemid 30118120)
7. Fletcher C, Sawchuk R, Chinnock B, de Miranda P, Balfour Jr HH. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 1986;40:281-6. (Pubitemid 16017854)
8. Snell GI, Kotsimbos TC, Levvey BJ, Skiba M, Rutherford DM, Kong DC, et al. Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis. J Antimicrob Chemother 2000;45:511-6. (Pubitemid 30199145)
9. Kimberlin DW, Acosta EP, Sánchez PJ, Sood S, Agrawal V, Homans J, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008;197:836-45. (Pubitemid 351417006)
10. Wiltshire H, Paya CV, Pescovitz MD, Humar A, Dominguez E, Washburn K, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005;79:1477-83. (Pubitemid 40847577)
11. Scott JC, Partovi N, Ensom MH. Ganciclovir in solid organ transplant recipients: is there a role for clinical pharmacokinetic monitoring? Ther Drug Monit 2004;26:68-77.
12. Vethamuthu J, Feber J, Chretien A, Lampe D, Filler G. Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children. Pediatr Transplant 2007;11:301-5. (Pubitemid 46570151)
13. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A 2000;97:8039-44. (Pubitemid 30460769)
14. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000;356:645-9. (Pubitemid 30627592)
15. Whitley RJ, Cloud G, Gruber W, Storch GA, Demmler GJ, Jacobs RF, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1997;175:1080-6. (Pubitemid 27176494)
16. Kimberlin DW, Lin CY, Sánchez PJ, Demmler GJ, Dankner W, Shelton M, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003;143:16-25. (Pubitemid 36928564)
17. Vaudry W, Ettenger R, Jara P, Varela-Fascinetto G, Bouw MR, Ives J, et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant 2009;9:636-43.